{"url":"https://lda.senate.gov/api/v1/filings/f04b236b-b838-4a67-ba65-48bc79bd2d0d/","filing_uuid":"f04b236b-b838-4a67-ba65-48bc79bd2d0d","filing_type":"RR","filing_type_display":"Registration","filing_year":2018,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/f04b236b-b838-4a67-ba65-48bc79bd2d0d/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Priscilla Chatman","dt_posted":"2018-12-18T20:21:57-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"13601 Belle Chasse Blvd","registrant_address_2":"Suite 316","registrant_different_address":null,"registrant_city":"Laurel","registrant_state":"MD","registrant_zip":"20707","registrant":{"id":400678024,"url":"https://lda.senate.gov/api/v1/registrants/400678024/","house_registrant_id":null,"name":"CHATMAN, LLC","description":"consulting firm","address_1":"13601 Belle Chasse Blvd","address_2":"Suite 316","address_3":null,"address_4":null,"city":"Laurel","state":"MD","state_display":"Maryland","zip":"20707","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PRISCILLA CHATMAN","contact_telephone":"+1 202-309-2777","dt_updated":"2022-04-06T16:07:54.918677-04:00"},"client":{"id":194082,"url":"https://lda.senate.gov/api/v1/clients/194082/","client_id":48,"name":"THE LIVINGSTON GROUP FOR TITAN PHARMACEUTICALS","general_description":"Pharmaceutical, makes and markets Probuphine, an implant to treat opioid addiction.","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-12-03"},"lobbying_activities":[{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"FDA labeling change for Probuphine","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":54941,"prefix":"ms","prefix_display":"MS.","first_name":"PRISCILLA","nickname":null,"middle_name":null,"last_name":"CHATMAN","suffix":"jd","suffix_display":"JD"},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"FDA labeling change for Probuphine","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":54941,"prefix":"ms","prefix_display":"MS.","first_name":"PRISCILLA","nickname":null,"middle_name":null,"last_name":"CHATMAN","suffix":"jd","suffix_display":"JD"},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"FDA labeling change for Probuphine","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":54941,"prefix":"ms","prefix_display":"MS.","first_name":"PRISCILLA","nickname":null,"middle_name":null,"last_name":"CHATMAN","suffix":"jd","suffix_display":"JD"},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"LAW","general_issue_code_display":"Law Enforcement/Crime/Criminal Justice","description":"FDA labeling change for Probuphine","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":54941,"prefix":"ms","prefix_display":"MS.","first_name":"PRISCILLA","nickname":null,"middle_name":null,"last_name":"CHATMAN","suffix":"jd","suffix_display":"JD"},"covered_position":null,"new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}